PARP INHIBITOR
Clinical trials for PARP INHIBITOR explained in plain language.
Never miss a new study
Get alerted when new PARP INHIBITOR trials appear
Sign up with your email to follow new studies for PARP INHIBITOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat ovarian cancer: drug combo trial launches
Disease control Recruiting nowThis study tests a combination of two drugs, vismodegib and atezolizumab, in people with ovarian, fallopian tube, or peritoneal cancer that no longer responds to platinum-based chemotherapy. The goal is to see if this treatment can shrink tumors or slow the disease. About 48 part…
Matched conditions: PARP INHIBITOR
Phase: PHASE2 • Sponsor: Ronald Buckanovich • Aim: Disease control
Last updated May 17, 2026 01:46 UTC
-
New cancer drug shows promise in early trial for Hard-to-Treat tumors
Disease control Recruiting nowThis study tests a new drug called SPR1020 in people with advanced solid tumors that have not responded to other treatments. The drug is designed to target cancer cells with specific genetic changes while causing fewer side effects than older similar drugs. The trial will first f…
Matched conditions: PARP INHIBITOR
Phase: PHASE1, PHASE2 • Sponsor: Shanghai SciBrunch Therapeutics Co., Ltd. • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New telehealth program aims to ease fatigue in ovarian cancer patients
Symptom relief Recruiting nowThis study tests a supportive telehealth program called REVITALIZE to see if it can reduce how much fatigue interferes with daily life for adults with advanced ovarian cancer who are taking PARP inhibitor maintenance therapy. About 240 participants will either receive the REVITAL…
Matched conditions: PARP INHIBITOR
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated May 15, 2026 11:55 UTC